• Ismail Yigitdol, Erdinc Gulumsek, Derya Demirtas, Mustafa Lutfullah Ardic, BaylanFiliz AlkanFA0000-0003-3117-7768Department of Biochemistry, University of Sutcu Imam, Kahramanmaras, Turkey., Huseyin Ali Ozturk, Fatih Necip Arici, Taner Seker, and Hilmi Erdem Sumbul.
• Department of Internal Medicine, University of Health Sciences-Adana City Training and Research Hospital, Adana, Turkey. ismail.yigitdol@gmail.com.
• Ir J Med Sci. 2024 Jun 1; 193 (3): 123912471239-1247.

BackgroundAsprosin is an emerging biomarker that plays a role in metabolic diseases. This study investigates asprosin as a predictive marker for coronary artery disease (CAD) severity in diabetic patients.MethodsDiabetic patients (n = 181) and healthy controls (n = 60) were analyzed. CAD severity was assessed using SYNTAX score. Diabetic patients were divided into 3 groups. Group 1 = patients without CAD, group 2 = patients with low SYNTAX score, and group 3 = patients with moderate-high SYNTAX score. Asprosin levels were measured for all participants using an enzyme-linked immunosorbent assay (ELISA).ResultsAsprosin levels were significantly higher in patient group compared to control group (p < 0.001). Asprosin levels were significantly higher in group 3 compared to group 1 and group 2 (p = 0.002). In logistic regression analysis, asprosin levels independently predicted patients with moderate-high SYNTAX scores. According to this analysis, 1 ng/mL increase in asprosin level was found to increase the risk of having moderate-high SYNTAX score by 14.1%. When the threshold value of asprosin level was set as 22.17 ng/mL, it predicted patients with moderate-high SYNTAX score with 63.6% sensitivity and 62.6% specificity. In multivariate regression analysis, SYNTAX score independently correlated with asprosin level.ConclusionThis is the first study in the literature to demonstrate a positive correlation between asprosin levels and SYNTAX scores in diabetic patients with CAD. More comprehensive studies with larger groups are needed.© 2024. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

23 keywords...

hide…